Literature DB >> 1362729

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method.

J C Vergniol1, R Bruno, G Montay, A Frydman.   

Abstract

A rapid, selective and reproducible high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the determination of the anti-cancer agent Taxotere in biological fluids. The method involves a solid-phase extraction step (C2 ethyl microcolumns) using a Varian Advanced Automated Sample Processor (AASP) followed by reversed-phase HPLC. The validated quantitation range of the method is 10-2500 ng/ml in plasma with coefficients of variation < or = 11%. The method is also suitable for the determination of Taxotere in urine samples under the same conditions. The method was applied in a phase I tolerance study of Taxotere in cancer patients, allowing the pharmacokinetic profile of Taxotere to be established.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1362729     DOI： 10.1016/0378-4347(92)80333-l

Source DB:  PubMed          Journal:  J Chromatogr


  14 in total

1.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

Review 2.  Clinical pharmacokinetics of docetaxel.

Authors:  S J Clarke; L P Rivory
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of docetaxel : recent developments.

Authors:  Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.

Authors:  Johnson Chen; Casilda Balmaceda; Jeffrey N Bruce; Michael B Sisti; May Huang; Ying Kuen K Cheung; Guy M McKhann; Robert R Goodman; Robert L Fine
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

6.  A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.

Authors:  C J Ardiet; B Tranchand; S Zanetta; A Guillot; E Bernard; M Peguy; P Rebattu; J P Droz
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients.

Authors:  Barrie R Cassileth; Naiyer Rizvi; Gary Deng; K Simon Yeung; Andrew Vickers; Stacey Guillen; Derek Woo; Marci Coleton; Mark G Kris
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-07       Impact factor: 3.333

8.  A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.

Authors:  Edward S Kim; Ann M Mauer; William N William; Hai T Tran; Diane Liu; Jack J Lee; Paul Windt; Waun K Hong; Everett E Vokes; Roy S Herbst
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

9.  Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.

Authors:  M C Launay-Iliadis; R Bruno; V Cosson; J C Vergniol; D Oulid-Aissa; M Marty; M Clavel; M Aapro; N Le Bail; A Iliadis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.

Authors:  A Fajac; J Gligorov; K Rezai; P Lévy; E Lévy; F Selle; K Beerblock; D Avenin; P Saintigny; S Hugonin; J-F Bernaudin; F Lokiec
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.